Workshop Day

Tuesday 25th July 2023

Morning Workshop

09:00 – 12:00 am
Workshop A

Avoiding the Niche Therapeutic Label: Exploring Next Generation Targets

  • Erik Mittra Director of Targeted Radionuclide Therapy, OHSU - Oregon Health & Science University


Targeted radiopharmaceuticals have been tested thoroughly on prostate cancer but to overcome the

fate of being relegated to a very niche indication only, TRPs need to be trailed on other targets. This

workshop will explore the rationale, prioritization criteria and key considerations for:

  • Neuroendocrine tumors
  • Breast Cancer
  • Lung Cancer
  • Haem cancers

09:00 – 12:00 am
Workshop C

Circumventing Supply Chain Issues


To avoid the huge pitfalls associated the roll out of Pluvicto, there is an urgent need to address supply issues. As more radiopharmaceuticals plants and reactors are developed by the likes of Rosotom and NuScale Power, the future looks hopeful.

This workshop will:

  • Compare the various radionuclides in their supply
  • Discuss the necessary steps to establishing infrastructure and logistics that will underpin a robust supply chain
  • Strategize ways to ensure there is a reliable source of radioisotopes to fuel clinical trials

12:10 pm Afternoon Lunch Break & Networking

12:59 pm Afternoon Workshop

13:00 – 16:00
Workshop B

Unlocking the Power of Dosimetry in Nuclear Medicine: Bridging the Gap between Theory & Practice


Integral to the era of targeted radionuclide therapies being highly personalized is getting

dosimetry right. Not only does dosimetry improve patient selection, but it also aims to minimize toxicity associated with the unavoidable irradiation of normal organs. Join this workshop to:

  • Get a deeper insight into the concept of dosimetry
  • Understand how to effectively conduct dosimetry calculations
  • Achieve personalization for each patient with reduced toxicity
  • Boost your regulatory applications through improved safety

13:00 – 16:00
Workshop D

Moving on From Monotherapies: Constructing Rational Combinations

  • Munir Ghesani Chief of Nuclear Medicine, Icahn School of Medicine at Mount Sinai


As the whole oncology field is abuzz with combination approaches, the targeted radionuclide

therapy space is no exception. This field is able to take two different combination routes: theranostics and dual therapy combinations.

This workshop will explore:

  • The two-birds-one-stone approach of harnessing the full potential of radionuclides through combining diagnostic agents with therapeutic agents
  • Overcoming monotherapy limitations with radionuclides as a lead combination partner: enhancing DDR inhibition and immunotherapies to avoid resistance and low efficacy
  • Evaluating the implications of toxicity when pursuing combination treatments